EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dependence of NPPS creates a targetable vulnerability in RAS-mutant cancers

Rui-Xue Xia, Pei-Chen Zou, Jun-Ting Xie, Ya-Bin Tang, Miao-Miao Gong, Fu Fan, Ayinazhaer Aihemaiti, Yu-Qing Liu, Ying Shen, Bin-Bing S Zhou, Liang Zhu, Hui-Min Lei

Acta Pharmacologica Sinica · 2025

DOI: 10.1038/s41401-024-01409-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Pharmacologica Sinica, 2025. Verfasst von Rui-Xue Xia und 11 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Pediatric Translational Medicine Institute, Shanghai Children's Medical Cente…. Hauptthemen laut MEDLINE: Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RAS is the most frequently mutated oncoprotein for cancer driving. Understanding of RAS biology and discovery of druggable lynchpins in RAS pathway is a prerequisite for targeted therapy of RAS-mutant cancers. The recent identification of KRAS G12C inhibitor breaks the “undruggable” curse on RAS and has changed the therapy paradigm of KRAS-mutant cancers. However, KRAS mutations, let alone KRAS G12C mutation, account for only part of RAS-mutated cancers. Targeted therapies for cancers harboring other RAS mutations remain the urgent need. In this study we explored the pivotal regulatory molecules that allow for broad inhibition of RAS mutants. By comparing the expression levels of nucleotide pyrophosphatase (NPPS) in a panel of cell lines and the functional consequence of increased NPPS expression in RAS-mutant cells, we demonstrated that cancer cells with various kinds of RAS mutations depended on NPPS for growth and survival, and that this dependence conferred a vulnerability of RAS-mutant cancer to treatment of NPPS inhibition. RAS-mutant cells, compared with RAS-wildtype cells, bored and required an upregulation of NPPS. Transcriptomics and metabolomics analyses revealed a NPPS-dependent hyperglycolysis in RAS-mutant cells. We demonstrated that NPPS promoted glucose-derived glycolytic intermediates in RAS-mutant cells by enhancing its interaction with hexokinase 1 (HK1), the enzyme catalyzing the first committed step of glycolysis. Pharmacological inhibition of NPPS-HK1 axis using NPPS inhibitor Enpp-1-IN-1 or HK1 inhibitor 2-deoxyglucose (2-DG), or genetic interfere with NPPS suppressed RAS-mutant cancers in vitro and in vivo. In conclusion, this study reveals an unrecognized mechanism and druggable lynchpin for modulation of pan-mutant-RAS pathway, proposing a new potential therapeutic approach for treating RAS-mutant cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MutationHumansAnimalsCell Line, TumorPyrophosphatasesNeoplasmsProto-Oncogene Proteins p21(ras)MiceAntineoplastic AgentsCell Proliferation

Stichwörter der Autor:innen

HK1NPPSRAS-mutant cancersglycolysis

Substanzen

PyrophosphatasesProto-Oncogene Proteins p21(ras)Antineoplastic AgentsKRAS protein, human

Autor:innen und Institutionen

  • Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127,…
  • Department of Pharmacology and Chemical Biology, College of Basic Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
  • Department of Pharmacology and Chemical Biology, College of Basic Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. binbing_s_zhou@yahoo.com.
  • Department of Pharmacology and Chemical Biology, College of Basic Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. jyzhul@shsmu.edu.cn.
  • Department of Pharmacology and Chemical Biology, College of Basic Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. leihuimin@shsmu.edu.cn.

Zitieren

APA

Xia, R. X., Zou, P. C., Xie, J. T., Tang, Y. B., Gong, M. M., Fan, F., Aihemaiti, A., Liu, Y. Q., Shen, Y., Zhou, B. S., Zhu, L., & Lei, H. M. (2025). Dependence of NPPS creates a targetable vulnerability in RAS-mutant cancers. Acta Pharmacologica Sinica. https://doi.org/10.1038/s41401-024-01409-2

Vancouver

Xia RX, Zou PC, Xie JT, Tang YB, Gong MM, Fan F, et al. Dependence of NPPS creates a targetable vulnerability in RAS-mutant cancers. Acta Pharmacologica Sinica. 2025. doi:10.1038/s41401-024-01409-2

BibTeX
@article{Xia2025,
  author = {Xia, Rui-Xue and Zou, Pei-Chen and Xie, Jun-Ting and Tang, Ya-Bin and Gong, Miao-Miao and Fan, Fu and Aihemaiti, Ayinazhaer and Liu, Yu-Qing and Shen, Ying and Zhou, Bin-Bing S and Zhu, Liang and Lei, Hui-Min},
  title = {Dependence of NPPS creates a targetable vulnerability in RAS-mutant cancers},
  journal = {Acta Pharmacologica Sinica},
  year = {2025},
  doi = {10.1038/s41401-024-01409-2}
}
Kostenlos starten →